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DObjective: In patients with pulmonary dysfunction, it is unclear whether a less-invasive approach for aortic
valve replacement is well tolerated or even beneficial. We investigated whether a partial upper J-incision for aor-
tic valve replacement leads to more favorable outcomes than a full sternotomy in patients with chronic lung
disease by using forced expiratory volume in 1 second as a surrogate.
Methods: From January 1995 to July 2010, 6931 patients underwent primary isolated aortic valve replacement;
655 had forced expiratory volume in 1 second measured and expressed as percent of predicted (FEV1%; 368 via
J-incision, 287 via full sternotomy). Postoperative outcomes were compared among 223 propensity-matched
pairs.
Results: Patients diagnosed with chronic lung disease had longer median intensive care unit (41 vs 27 hours,
P¼ .001) and postoperative (7.1 vs 6.1 days, P<.0001) lengths of stay than those without chronic lung disease.
At normal values of FEV1%, little difference was observed in either of these times for J-incision versus full
sternotomy; however, at progressively lower FEV1%, these times lengthened, with increasing benefit for
J-incision. Among propensity-matched patients, other postoperative complications were similar. Early survival
(93% vs 89% at 1 year, P ¼ .07) was possibly higher in matched patients with J-incision, but late survival was
similar (P ¼ .9). Patients with FEV1% less than 50 who underwent J-incision had the greatest survival advan-
tage, which persisted for 5 years.
Conclusions: In patients with preoperative respiratory dysfunction, a less-invasive partial upper J-incision for
aortic valve replacement can lead to more favorable outcomes than a full sternotomy, including shorter intensive
care unit and postoperative lengths of stay and better early survival, which are amplified with decreasing pul-
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Patients with severe respiratory dysfunction and chronic
lung disease (CLD) are being seen more frequently, partic-
ularly for various types of transcatheter aortic valve replace-
ment (AVR).1Whether these patients would tolerate or even
benefit from a surgical AVR via a less-invasive J-incision
rather than a full sternotomy is unknown. Even among
our own group of surgeons, the less-invasive approach has
not been adopted universally.
A paramedian incision for AVR was introduced in 19962;
subsequently, a partial upper J-incision (hereafter referred to
simply as ‘‘J-incision’’), introduced in 1997,3 has been gain-
ing acceptance.2-5 We5 and others1-3,5-10 have reported that
the J-incision has multiple benefits compared with
a standard median sternotomy, including less surgical
trauma, less pain, shorter ventilation time, and shorter
intensive care unit (ICU) and hospital lengths of stay.2-10
Because of these possible advantages, a J-incision mightrdiovascular Surgery c Volume 147, Number 1 355
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
CABG ¼ coronary artery bypass grafting
CLD ¼ chronic lung disease
FEV1 ¼ forced expiratory volume in 1 second
FEV1% ¼ forced expiratory volume in 1 second,
percent of predicted
ICU ¼ intensive care unit
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Dbe beneficial for high-risk patients, such as those with pul-
monary dysfunction, a well-established risk factor for mor-
tality and morbidity after cardiac surgery.5,11,12
The J-incision may stabilize the sternum and thoracic
cage, resulting in better postoperative pulmonary func-
tion.3-5 Furthermore, it is believed that less spreading of
the incision, not interfering with the diaphragm, and less
tissue dissection might facilitate earlier postoperative
respiratory recovery.5,13 Yet these perceived benefits have
not been studied in the specific high-risk group of patients
with pulmonary dysfunction.3,4,6-14
Such a study is challenging because pulmonary dysfunc-
tion comprises a broad spectrum of lung diseases and is
complex to define. Spirometry is the most common pulmo-
nary function test used to assess severity and operative risks
in these patients.15 It is not influenced by observer bias and
provides markers for degree of lung function impairment.
Therefore, we investigated whether a J-incision for AVR
leads to more favorable outcomes in patients with pulmo-
nary dysfunction, using forced expiratory volume in 1 sec-
ond, percent of predicted (FEV1%), as a surrogate.PATIENTS AND METHODS
Patients
From January 1995 to July 2010, 6931 patients underwent primary iso-
lated AVR, of whom 655 had preoperative spirometry data available
(J-incision in 368 and full sternotomy in 287). Patients undergoing con-
comitant mitral valve surgery or coronary artery bypass grafting (CABG)
were excluded, as were those with active endocarditis. Mean age was
68  13 years, and 54% were men.
Data
Data were retrieved from the prospective Cardiovascular Information
Registry, supplemented with information from the Echocardiography data-
base. Preoperative spirometry datawere obtained from the institution’s pro-
spectively recorded Pulmonary Function Laboratory database.
Preoperative forced expiratory volume in 1 second (FEV1) and forced vital
capacity values were normalized to percent of predicted by the National
Health and Nutrition Examination Survey algorithm.16 All data were ap-
proved for use in research by the Institutional Review Board, with patient
consent waived.
Surgical Technique
Conventional general anesthesia was used in all patients regardless of
surgical approach. Patients who underwent less-invasive J-incision had
an 8- to 10-cm skin incision. The upper sternumwas divided in the midline,356 The Journal of Thoracic and Cardiovascular Surgand this sternotomy was extended into the right fourth intercostal space
forming a J.3,4 The diaphragm was not interfered with, and spreading the
incision was limited to approximately 5 cm, minimizing tension and
flexing of the posterior rib attachments to the vertebral bodies. Approach
to the aortic valve was via an oblique aortotomy carried into the
noncoronary cusp or a transverse aortotomy above the sinutubular
junction, and choice of valve type was at the discretion of the surgeon.
AVR was then carried out according to the surgeon’s standard technique.
Vacuum-assisted cardiopulmonary bypass with central cannulation was
used in all patients. Intraoperative transfusions, anesthetic technique, and
timing of extubation were at the anesthesiologists’ and critical care team’s
discretion. Intraoperative and postoperative transfusions were not driven by
protocolized transfusion triggers, except that Cleveland Clinic has long ad-
vocated blood-conservation practices.
Outcomes
Outcomes assessed included intraoperative support (myocardial is-
chemic time, cardiopulmonary bypass time), postoperative in-hospital
mortality and morbidity (defined in accordance with the Society of
Thoracic Surgeons National Database: http://www.ctsnet.org/file/
rptDataSpecifications252_1_ForVendorsPGS.pdf), blood product use,
time to extubation, ICU and postoperative lengths of stay, and long-
term survival.
Survival was assessed by active follow-up at 2 years and then every
5 years using an Institutional Review Board–approved questionnaire with
patient consent required. Vital status was supplemented with data from
the Social Security Death Master File with a censoring date of February
15, 2011. A total of 2423 patient-years of combined active and passive
follow-up for vital status were available for analysis, with a median
follow-up of 2.7 years; 25% of survivors were followed more than 6.1
years, and 10% were followed more than 9.2 years. Thus, survival curves
are truncated at 10 years. The seemingly short median follow-up is caused
by a combination of an escalating volume of AVRs in recent years5 and in-
creased use of preoperative spirometry (Figure E1).
Data Analysis
All analyses were performed using SAS statistical software (v9.1; SAS
Institute Inc, Cary, NC).
Spirometry and Chronic Lung Disease
Trends in spirometry values according to clinical diagnosis of CLD
were estimated by logistic regression analysis, as were factors associated
with performing preoperative spirometry.
Factors Associated With Surgical Approach
A number of patient characteristics differed between those receiving
a less-invasive J-incision and those undergoing full sternotomy, including
spirometry data (Table 1). Logistic regression analysis was used to iden-
tify statistically significant preoperative differences. A parsimonious
model was developed using bagging.17,18 Briefly, a patient is selected at
random to begin building a new data set, and this random selection
process is repeated until the new data set is the same size as the
original. On average, approximately one third of patients are not
selected, and therefore a number of patients are duplicated. This is
known as a bootstrap sample; 1000 such bootstrap data sets were built.
Each was then analyzed by automated stepwise regression with
a P value criterion to retain of .05 using the candidate risk factors listed
in Appendix E1. This resulted in 1000 regression models. These models
were then aggregated by counting the frequency of occurrence of variables
in the 1000 models. We consolidated counts of closely correlated variables
such as linearizing transformations of scale. We then selected variables for
the final model if they appeared in 50% or more of the analyses (a mea-
sure of reliability).ery c January 2014
TABLE 1. Patient characteristics and operative details by surgical approach
Variable
All patients Propensity-matched patients
J-incision (n ¼ 368) Full (n ¼ 287) J-incision (n ¼ 223) Full (n ¼ 223)
n*
No. (%) or
mean ± SD n*
No. (%) or
mean ± SD n*
No. (%) or
mean ± SD n*
No. (%) or
mean ± SD
Demography
Women 368 177 (48) 287 126 (44) 223 105 (47) 223 104 (47)
Age (y) 368 69  12 287 67  13 223 67  13 223 68  13
BMI (kg$m2) 349 30  7.2 261 30  8.0 208 30  7.6 203 31  8.0
NYHA functional class 288 225 174 172
I 54 (19) 36 (16) 32 (18) 31 (18)
II 145 (50) 114 (51) 89 (51) 85 (49)
III 80 (28) 67 (30) 45 (26) 52 (30)
IV 9 (3.1) 8 (3.6) 8 (4.6) 4 (2.3)
Indication for operation 366 285 222 222
Degenerative 360 (98) 268 (94) 216 (97) 209 (94)
Other 6 (1.6) 17 (6.0) 6 (2.7) 13 (5.8)
Cardiac comorbidity
LVEF (%) 358 56  8.7 281 52  14 217 56  9.0 218 55  11
Aortic valve area (cm2) 326 0.7  0.2 226 0.7  0.4 192 0.7  0.2 184 0.7  0.2
Aortic valve gradient (mm Hg)
Mean 334 48  16 245 47  18 197 48  16 196 47  17
Peak 334 82  23 245 80  29 197 82  24 196 81  28
LV mass index (g$m2) 327 118  36 240 136  45 193 125  38 187 126  39
LA volume index (mL$m2) 316 18  10 229 21  11 184 19  11 180 19  11
Tricuspid regurgitation more
than moderate
343 43 (12) 271 24 (8.8) 214 25 (12) 209 16 (7.6)
Atrial fibrillation/flutter 346 17 (4.9) 257 7 (2.7) 207 9 (4.3) 199 7 (3.5)
Noncardiac comorbidity
Hypertension 368 255 (69) 287 200 (70) 223 157 (70) 223 157 (70)
CLD 368 133 (36) 287 117 (41) 223 86 (39) 223 88 (39)
Past or current smoking 367 238 (65) 286 183 (64) 223 141 (63) 223 149 (67)
FEV1% 368 84  23 287 78  21 223 80  21 223 80  21
FVC (% of predicted) 368 89  20 287 81  19 223 85  20 223 83  19
FEV1/FVC 368 70  12 287 72  11 223 71  12 223 72  11
SD, Standard deviation; BMI, body mass index; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; LV, left ventricle; LA, left atrial; CLD, chronic lung
disease; FEV1%, forced expiratory volume in 1 second, percent of predicted; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second. *Number of patients with
data available.
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To reduce the influence of selection bias for surgical approach, we used
propensity matching.19 After establishing the parsimonious model for ap-
proach (Table E1), we added other variables, identified in Appendix E1,
representing groups of patient factors that might be related to unrecorded
selection factors (saturated model). A propensity score was then calculated
for each patient by solving the saturated model for the probability of under-
going a full sternotomy versus a J-incision.
By using only the propensity score, 223 patients (78%) who received
a J-incision were matched to patients who received a full sternotomy us-
ing a greedy matching strategy. These matched patients spanned the ma-
jority of patients (Figure E2, A), although patients with extreme
propensity scores (strongly favoring J-incision or strongly favoring full
sternotomy) represent unmatched patients whose propensity scores devi-
ated more than 0.2 from those of patients receiving a full sternotomy. The
result was 2 groups of patients well matched for characteristics (Table 1
and Figure E2, B). In addition, because the number of events was insuf-
ficient to perform an extensive multivariable analysis, the propensity
score itself was used additionally as a risk-adjustment factor for analyses
of survival.20The Journal of Thoracic and CaManaging Missing Covariable Data
We used 5-fold multiple imputation using a Markov Chain Monte Carlo
technique to impute missing covariable values in multivariable analyses
(SAS PROC MI, SAS Institute, Inc). The first imputation data set was used
for model development, followed by fitting the final model to each of the
other 4 data sets and then aggregating the results (SASPROCMIANALYZE,
SAS Institute, Inc).
Comparisons
Continuous variables were compared using theWilcoxon rank-sum test.
Categoric variables were compared using the chi-square test or Fisher exact
test when frequency was less than 5.
The unadjusted relationship of FEV1% and intubation time, ICU
length of stay, and postoperative length of stay was characterized semi-
parametrically using spline smoothing, stratified by surgical approach
(SPlus v8.04, 2007, Insightful Corp, Seattle, Wash). The resulting
smoothed curves for these outcomes were superimposed on box plots
for 4 equal intervals according to approach. Each relation was adjusted
for preoperative variables (Appendix E1) using linear regression and bag-
ging as described earlier.rdiovascular Surgery c Volume 147, Number 1 357
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method and parametrically by amultiphase hazardmodel.21 (For additional
details, see http://my.clevelandclinic.org/professionals/software/hazard/
default.aspx). The parametric model was used to resolve a number of
phases of instantaneous risk of death (hazard function) and to estimate
shaping parameters. Risk factors for each hazard phase were identified si-
multaneously using bagging, as described previously.
Presentation
Continuous variables are summarized as mean standard deviation and
as 15th, 50th (median), and 85th percentiles for skewed data distributions.
Categoric variables are summarized by frequencies and percentages. Para-
metric estimates are accompanied by asymmetric 68% confidence bands,
comparable to 1 standard error.RESULTS
Preoperative Spirometry and History of Chronic
Lung Disease
Preoperative spirometry was performed in only 10% to
15% of patients before 2006, but since then that proportion
has increased to 30% to 45% (Figure E1). Spirometry
was performed preferentially in patients with a history of
smoking, clinical diagnosis of CLD, or higher risk
(Tables E2 and E3).
Lower spirometry values were progressively more
strongly associated with clinical history of CLD
(Figure E3). FEV1% was more discriminating than forced
vital capacity percent of predicted (lung-diffusing capacity
was available for only a minority of patients). Lower
FEV1% also was associated with older age, history of
smoking, heart failure, atrial fibrillation, kidney dysfunc-
tion, smaller aortic valve area, and lower ejection fraction
(Table E4).Preoperative Spirometry and Surgical Approach
Preoperative spirometry was strongly related to surgical
approach (Table 1), with full sternotomy apparently pre-
ferred for patients with poorer respiratory function. Full
sternotomy also was more common in patients with heart
failure, lower ejection fraction, impaired hepatic function,
and greater left ventricular mass (Table E1).FIGURE 1. Relationship of FEV1% to intubation time and ICU and post-
operative (Post-Op) lengths of stay. Box plots show 15th, 25th, 50th, 75th,
and 85th percentiles of data points for 4 equal intervals of FEV1% values
stratified by surgical approach. Solid lines represent spline fits for theIntubation Time
Preoperative FEV1% was not correlated with duration of
intubation, either unadjusted (P¼ .2) or adjusted for preoper-
ative variables (P¼ .4) (Figure 1, A). Patients in the full ster-
notomy group had a higher occurrence of respiratory
insufficiency (intubated >24 hours) than the propensity-
matched J-incision group (10% vs 5.1%, P ¼ .06; Table 2),
although mean duration of intubation was similar (15  6.3
hours vs 14  6.5 hours, respectively, P ¼ .4; Table 2).J-incision group, and dashed lines represent fits for the full sternotomy
group. A, FEV1% and intubation time (hours). B, FEV1% and ICU
stay. C, FEV1% and postoperative stay. FEV1, Forced expiratory volume
in 1 second; ICU, intensive care unit; LOS, length of stay.Length of Intensive Care Unit Stay
Patients with lower preoperative FEV1% had more pro-
longed ICU stays (P¼ .0002 unadjusted, P<.0001 adjusted358 The Journal of Thoracic and Cardiovascular Surgery c January 2014
TABLE 2. In-hospital outcomes by surgical approach, overall and in propensity-matched patients*
Outcome
Overall Propensity-matched
J-incision
(n ¼ 368)
Full sternotomy
(n ¼ 287)
P
J-incision
(n ¼ 223)
Full sternotomy
(n ¼ 223)
PNo. % No. % No. % No. %
Intubation time (h)y 14  6.4 15  6.2 .3 14  6.5 15  6.3 .4
ICU length of stay (h)z 22/27/78 24/31/120 .0007 22/26/79 24/29/96 .02
Postoperative length of stay (d)z 5/6/10 5/7/12 <.0001 5/6/10 5/7/11 .01
Respiratory insufficiency 16 5.3 30 14 .0005 9 5.1 18 10 .06
Stroke 3 0.82 2 0.69 .9 2 0.89 2 0.89 >.9
Renal failure 9 2.4 16 5.6 .04 6 2.7 9 4.0 .4
Myocardial infarction 0 0 0 0 — 0 0 0 0 —
Deep sternal wound infection 2 0.54 2 0.69 .8 2 0.89 0 0 .2
Sepsis/septicemia 4 1.1 6 2.1 .3 4 1.8 4 1.8 >.9
Return to OR for bleeding 11 3.0 11 3.8 .6 7 3.1 9 4.0 .6
Death 2 0.54 6 2.1 .07 2 0.89 4 1.8 .4
ICU, Intensive care unit;OR, operating room. *Morbidities as defined by and submitted to the Society of Thoracic Surgeons Adult Cardiac National Database. yMean standard
deviation. z15th/50th/85th percentiles.
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was longer in the full sternotomy group (median, 29 hours)
than in the propensity-matched J-incision group (median,
26 hours; P ¼ .02; Table 2).
Length of Postoperative Stay
Patients with lower preoperative FEV1% had more pro-
longed postoperative stays (P<.0001 unadjusted and ad-
justed for preoperative variables; Figure 1, C). Length of
postoperative stay was longer in the full sternotomy group
(median, 7 days) than in the matched J-incision group
(median, 6 days; P ¼ .01; Table 2).
Hospital Mortality and Complications
Among propensity-matched patients, hospital mortality
(1.8% full sternotomy vs 0.89% J-incision) and morbidity
were similar for patients with a full sternotomy and those
with a J-incision (Table 2).
Survival
Patients with lower preoperative FEV1% had lower
propensity-adjusted survival (Figure 2, A and Table 3).
This was particularly apparent in the full sternotomy group,
with confidence bands separating below an FEV1% of ap-
proximately 50. However, by 5 years, these curves con-
verged (Figure 2, B). Unadjusted survival was lower in
the early hazard phase after full sternotomy than after
J-incision; survival estimates at 6 months and 1, 5, and 10
years were 89%, 87%, 73%, and 48% in the full sternot-
omy group versus 95%, 94%, 80%, and 55% in the J-inci-
sion group, respectively (Figure E4). Risk-adjusted survival
was more similar (Figure E5), with the important interac-
tion of approach with FEV1% as noted in Table 3 and
Figure 2. Thus, lower preoperative FEV1% was an incre-
mental risk factor in the early hazard phase and both lowerThe Journal of Thoracic and CaFEV1% and full sternotomy in the late hazard phase, with
J-incision protective.
DISCUSSION
Principal Findings
This study has shown that with increasingly poor pulmo-
nary function, as measured by FEV1%, patients with CLD
derive a greater benefit from undergoing a less-invasive
J-incision for AVR than AVR performed through a full ster-
notomy. This is reflected in the results showing that postop-
erative respiratory insufficiency, defined as intubation for
more than 24 hours, was twice as high for full sternotomy,
and ICU and postoperative lengths of stay were longer, par-
ticularly in patients with lower FEV1%. Furthermore, hos-
pital mortality was twice as high for full sternotomy, and
later survival was worse, especially among patients with
low FEV1%. Indeed, the lower the FEV1%, the better
the 1-year survival for those undergoing a less-invasive
J-incision compared with those undergoing full sternotomy.
Even to 10 years, patients receiving a J-incision maintained
an approximate survival advantage of 8%, both unadjusted
and after propensity matching. Thus, this article confirms
for the first time the theoretic advantage of less interference
with respiratory function using the less-invasive approach,
and this is reflected in better respiratory outcomes and sur-
vival, particularly in high-risk patients with poor respiratory
function.
Clinical Implications
Pulmonary dysfunction in patients with CLD is a well-
documented risk factor for morbidity and mortality after
cardiac surgery. Analyses of large cardiac registries have re-
ported increased odds of in-hospital mortality by ratios of
1.4 to 1.6 among patients with versus without CLD.22-26
Reduction of lung function postoperatively is influencedrdiovascular Surgery c Volume 147, Number 1 359
TABLE 3. Incremental risk factors for death after aortic valve
replacement, with propensity for full sternotomy forced into model*
Factor Coefficient ± SE P
Early hazard phase
Lower FEV1%y 1.13  0.30 .0002
J-incision 0.37  0.85 .7
J-incision/FEV1% interaction 0.69  0.63 .3
Propensity for full sternotomy 0.94  0.71 .18
Late hazard phase
Lower FEV1%z 1.31  0.48 .007
J-incision 5.61  2.95 .06
Full sternotomy/FEV1% interaction 1.34  0.70 .06
Propensity for J-incision 0.23  0.62 .7
SE, Standard error; FEV1%, forced expiratory volume in 1 second, percent of pre-
dicted. *Adjusted for age, body mass index, New York Heart Association functional
class, aortic valve peak gradient, tricuspid valve regurgitation, peripheral arterial dis-
ease, previous stroke, diabetes, and blood urea nitrogen. y(FEV1%/81)1, inverse
transformation. zLn(FEV1%), logarithmic transformation.
FIGURE 2. Nomograms of 1- and 5-year risk-adjusted mortality accord-
ing to preoperative FEV1% stratified by approach. These nomograms rep-
resent solutions to the multivariable equation found in Table 3. A, Predicted
1-year mortality. B, Predicted 5-year mortality. FEV1, Forced expiratory
volume in 1 second.
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length of the sternal incision.13,22,23 Trauma to the
sternum, use of internal thoracic artery for bypass
grafting, opening the pleura, and placing chest tubes may
affect postoperative pulmonary function, especially in
patients with poor pulmonary reserve.27
Thus, surgical strategies should be modified in patients
with pulmonary dysfunction. Use of a J-incision may stabi-
lize the sternum and thoracic cage, resulting in better post-
operative pulmonary function and ability to cough and
breath.3,4,6,13 This advantage may be the result of less
surgical dissection, less spreading of the sternum, and
minimizing tension on the posterior rib head and
costovertebral ligaments, because the chest wall is not
opened like a trap door. Further, there is no interference
with the diaphragm or dissection along it. Also, with less
chest wall pain, patients may have less splinting of the
chest and thus breathe more deeply. Meta-analysis has
shown shorter intubation times after the J-incision
approach.9
We showed previously in a propensity-matched compar-
ison that a substantially higher proportion of matched360 The Journal of Thoracic and Cardiovascular Surgpatients were extubated in the operating room after a J-in-
cision than after full sternotomy (12% vs 1.6%,
P< .0001).5 Median time to extubation was also shorter
(5.2 hours [confidence limit, 2.5-12] vs 6.9 hours [confi-
dence limit, 3.6-21], P< .0001). FEV1% was higher im-
mediately after extubation in the J-incision group, with the
difference narrowing during the first 36 hours after sur-
gery. Of note, risk of respiratory failure was lower with
the J-incision (P ¼ .01).
These results confirm the need to modify our surgical
strategies for patients with severe pulmonary dysfunction
who are at high risk for postoperative morbidity and mortal-
ity after full sternotomy. This risk has been demonstrated re-
peatedly in patients undergoing CABG. Canver and
colleagues24 identified preoperative FEV1% as an impor-
tant predictor of 5-year survival in patients with CLD under-
going CABG. Preoperative FEV1 of less than 1.25 carried
a 7-fold higher risk of death during follow-up, with 9-year
survival of 42% versus 76% for those with higher FEV1.
Other studies have shown similar in-hospital mortality for
patients with mild to moderate CLD and worse outcomes
among those with severe CLD.25 Fuster and colleagues26
have demonstrated that operative mortality after CABG is
related to severity of CLD; mortality was 0.4% to 0.9%
in patients with FEV1% more than 60%, but 11% for
FEV1% of 40% to 59% and 54% for FEV1% less
than 40%.
Clinical implications are that the less-invasive J-incision
should be encouraged rather than avoided for high-risk pa-
tients with pulmonary disease. We therefore recommend
this approach for these patients.Study Limitations
Investigation of the influence of chronic obstructive pul-
monary disease or CLD on survival and morbidity afterery c January 2014
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measure degree of dysfunction. We chose to use FEV1%
as a surrogate, fully aware that other tests, such as lung dif-
fusion capacity testing and arterial blood gases, may have
added to the study’s predictive abilities. However, these
tests were not routinely available. Ideally, a randomized
trial between the less-invasive J-incision and full sternot-
omy should be performed in high-risk patients with severe
pulmonary dysfunction. On the basis of our experience
with this population, however, including the transcatheter
AVR trials,1 we do not have equipoise for such a trial.
We used propensity matching to compare patients receiv-
ing J-incision with those undergoing full sternotomy. How-
ever, propensity methods address only that portion of the
spectrum for which heterogeneity in practice is discovered
(virtual equipoise). As with randomized trials, it is tempting
to extrapolate beyond the confines of the overlapping por-
tions of the spectrum. Furthermore, at both extremes of
the spectrum, surgeons at the Cleveland Clinic during the
period of this study systematically performed J-incision or
full sternotomy for AVR. We acknowledge that selection
bias cannot be completely reversed by propensity-based
methods and, in this study, cannot completely overcome
distinct surgeon preferences, although we attempted to ad-
just for these. Treatment was not masked, and this could
have influenced ICU critical care management to an unmea-
surable extent.
This is also a single-institution study conducted at a high-
volume center, which may have decreased the differences in
outcomes between the 2 strategies and may limit its gener-
alizability. Nevertheless, time to extubation and spirometry
values would largely have been uninfluenced by potential
surgeon biases because these were determined or routinely
collected by respiratory therapists, anesthesiologists, inter-
ventionists, or nurses.
CONCLUSIONS
For patients with severe respiratory dysfunction, a less-
invasive partial upper J-incision for AVR can lead tomore fa-
vorable outcomes than full sternotomy, including shorter ICU
and postoperative lengths of stay and better early survival,
which are amplified with decreasing pulmonary function.
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FIGURE E1. Preoperative spirometry testing over time, 1997 to 2010
(n ¼ 2619, with 655 patients undergoing testing).
APPENDIX E1. Variables used in analyses
Demographics
Age (y),* sex,* race,* height (cm), weight (kg), body surface area (m2),
body mass index (kg$m2)*
Preoperative symptoms
NYHA functional class (I-IV)*
Cardiac comorbidity
Complete heart block,* ventricular arrhythmia,* chronic heart failure,*
previous cardiac operation
Noncardiac comorbidity
Hypertension,* peripheral arterial disease,* diabetes,* stroke,*
smoking*
Laboratory medicine
Blood urea nitrogen (mg$dL1),* total cholesterol (mg$dL1),* low-
density lipoprotein (mg$dL1),* high-density lipoprotein
(mg$dL1),* creatinine (mg$dL1),* hematocrit (%),* bilirubin
(mg$dL1),* triglycerides (mg$dL1)
Valve pathology
AV regurgitation, AV stenosis,* mitral valve regurgitation, tricuspid
valve regurgitation, AV native
AV etiology
Rheumatic, degenerative
LV size
LV end-diastolic volume (mL),* LV end-systolic volume (mL),* LV
diastolic diameter (cm), LV systolic diameter (cm), LV mass (g),*
posterior wall thickness (cm), septal thickness (cm)
LV function
Myocardial infarction,* ejection fraction (%),* fractional
shortening (%)*
Left atria
Left atrial diameter (cm), left atrial volume (mL),* AV systolic area
(cm2),* AV mean gradient (mm Hg),* AV peak gradient (mm Hg)*
Spirometry
FEV1, percent of predicted*; FVC, percent of predicted; FEV1/FVC
ratio*
Experience
Years since January 1, 1995*
NYHA, New York Heart Association; AV, aortic valve; LV, left ventricular; FEV1,
forced expiratory volume in 1 second; FVC, forced vital capacity. *Variables included
in propensity model.
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FIGURE E3. Relationship of clinical diagnosis of CLD to spirometry
values. Closed circles represent percentages in grouped data, and solid
line with its 68% confidence limits is a univariable logistic regression
estimate of the trend. A, FEV1%. B, FVC expressed as percent of pre-
dicted. C, FEV1/FVC. CLD, Chronic lung disease; FEV1, forced expira-
tory volume in 1 second; FVC, forced vital capacity.
FIGURE E2. Propensity score matching for J-incision versus full sternot-
omy. A, Mirrored histogram of distribution of propensity scores for J-inci-
sion versus full sternotomy groups. Darkened area represents matched
patient pairs. B, Covariable balance for selected variables before (closed
triangles) and after (closed squares) propensity matching, expressed as
standardized difference.1 NYHA, New York Heart Association; FEV1,
forced expiratory volume in 1 second; FEV1%, forced expiratory volume
in 1 second, percent of predicted; FVC, forced vital capacity; HDL, high-
density lipoprotein; LV, left ventricular; PAD, peripheral arterial disease.
1. Austin PC, Mamdani MM. A comparison of propensity score methods:
a case-study estimating the effectiveness of post-AMI statin use. Stat Med.
2006;25:2084-106.
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FIGURE E5. Mortality after AVR, stratified by approach (matched pa-
tient pairs). A, Survival. Each symbol represents a death positioned on a ver-
tical axis by the Kaplan–Meier estimator, vertical bars are confidence
limits equivalent to 1 standard error, and numbers in parentheses are pa-
tients still alive and traced at 1, 3, 5, and 10 years. Solid lines are parametric
survival estimates enclosed within dashed 68% confidence bands equiva-
lent to 1 standard error. B, Hazard function. Parametric estimates (solid
lines) are enclosed within dashed confidence bands equivalent to 1 stan-
dard error. AVR, Aortic valve replacement.
FIGURE E4. Unadjusted survival after aortic valve procedure stratified
by approach. Each symbol represents a death positioned on a vertical
axis by the Kaplan–Meier estimator, vertical bars are confidence limits
equivalent to 1 standard error (SE), and numbers in parentheses are patients
still alive and traced at 1, 3, 5, and 10 years. Solid lines are parametric sur-
vival estimates enclosed within dashed 68% confidence bands equivalent
to 1 SE.
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TABLE E1. Variables associated with surgical approach: Full
sternotomy versus J-incision
Variable Coefficient ± SE P
Reliability
(%)*
Factors favoring full sternotomy
Spirometry
Lower FEV1%y 0.62  0.17 .0003 94
Higher FEV1/FVCz 1.6  0.33 <.0001 94
Greater left ventricular massx 0.0056  0.0024 .02 83
Heart failure 0.56  0.21 .008 88
Peripheral arterial disease 0.77  0.32 .02 72
Higher bilirubin 0.47  0.25 .06 52
Factor favoring J-incision
Higher EFk 0.67  0.27 .01 85
C-statistic of this parsimonious model is 0.701. SE, Standard error; FEV1%, forced
expiratory volume in 1 second, percent of predicted; FEV1, forced expiratory volume
in 1 second; FVC, forced vital capacity; EF, ejection fraction. *Percent of times factor
appeared in 1000 bootstrap models. yExp(FEV1%/81), exponential transformation.
z(FEV1%/FVC/72)2, squared transformation. xIndexed by body surface area.
k(EF/52)1, inverse transformation.
TABLE E2. Patient characteristics and operative details stratified by pulmonary function test (total n ¼ 2619)
Variable
Pulmonary function test (n ¼ 655) No pulmonary function test (n ¼ 1964)
Pn* No. (%) or mean ± SD n* No. (%) or mean ± SD
Demography
Women 655 303 (46) 1964 758 (39) .0005
Age (y) 655 68  13 1964 64  14 <.0001
BMI (kg$m2) 610 30  7.6 1699 29  6.8 .0002
NYHA functional class 513 1452 <.0001
I 90 (18) 379 (26)
II 259 (50) 788 (54)
III 147 (29) 249 (17)
IV 17 (3.3) 36 (2.5)
Indication for operation
Degenerative 651 628 (96) 1953 1828 (94) .006
Other 651 23 (3.5) 1953 125 (6.4) .006
Cardiac comorbidity
LVEF (%) 639 55  11 1834 55  10 .7
Aortic valve area (cm2) 552 0.71  0.27 1486 0.71  0.25 .5
Aortic valve gradient (mm Hg)
Mean 579 47  16 1588 50  18 .001
Peak 579 81  26 1593 84  28 .02
LV mass index (g$m2) 567 126  41 1547 134  47 <.0001
LA volume index (mL$m2) 545 19  11 1428 19  9.9 .5
Tricuspid regurgitation more than moderate 614 17 (2.8) 1840 24 (1.3) .01
Atrial fibrillation/flutter 603 24 (4.0) 1678 39 (2.3) .03
Noncardiac comorbidity
Hypertension 655 455 (69) 1964 1192 (61) <.0001
CLD 655 250 (38) 1964 104 (5.3) <.0001
Past or current smoking 653 421 (64) 1945 869 (45) <.0001
FEV1% 655 81  22 — — —
FVC (% of predicted) 655 86  20 — — —
FEV1/FVC 655 71  12 — — —
SD, Standard deviation; BMI, body mass index; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; LV, left ventricle; LA, left atrial; CLD, chronic lung
disease; FEV1%, forced expiratory volume in 1 second, percent of predicted; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity. *Number of patients with
data available.
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TABLE E3. Factors related to obtaining spirometry before aortic
valve surgery (n ¼ 2619; 655 patients with testing)
Variables associated with
preoperative spirometry testing
Coefficient
± SE P
Reliability
(%)*
Female 0.33  0.11 .002 60
History of CLD 2.37  0.14 <.0001 100
History of recent smoking 0.77  0.11 <.0001 100
Preoperative atrial fibrillation 0.78  0.31 .01 56
Higher triglycerides (mg$dL1) 0.32  0.11 .003 52
Lower preoperative AV mean
gradient (mm Hg)
0.007  0.003 .04 67
Higher NYHA functional class 0.28  0.08 .0006 84
More recent date of operation 0.18  0.01 .02 100
C statistic ¼ 0.799. SE, Standard error; CLD, chronic lung disease; AV, aortic valve;
NYHA, New York Heart Association. *Percent of times factor appeared in 1000 boot-
strap models.
TABLE E4. Variables associated with higher preoperative forced
expiratory volume in 1 second, percent of predicted
Variable
Coefficient
± SE P
Reliability
(%)*
Higher FEV1%
Male 3.5  1.6 .03 60
Older age
Exp(age) 97  21 <.0001 100
Age2 132  30 <.0001 100
Higher preoperative creatininey 3.2  1.2 .008 52
Higher HDL 0.12  0.05 .02 53
Greater aortic valve area 4.6  2.3 .04 79
Higher LVEFz 4.8  2.0 .02 57
Lower FEV1%
History of CLD 24  1.4 <.0001 100
History of smoking or recent
smoker
3.7  1.5 .01 100
History of heart failure 4.7  1.8 .007 86
Preoperative atrial fibrillation 12  3.6 .001 86
Lower preoperative BUNx 6.5  2.0 .002 64
Average R2 of this model is 0.436. SE, Standard error; FEV1%, forced expiratory vol-
ume in 1 second, percent of predicted;HDL, high-density lipoprotein; LVEF, left ven-
tricular ejection fraction; CLD, chronic lung disease; BUN, blood urea nitrogen.
*Percent of times factor appeared in 1000 bootstrap models. y(1/creatinine)2, inverse
squared transformation. z(EF/52)2, squared transformation. xLn(BUN), logarithmic
transformation.
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